Why in news?
The United States Food and Drug Administration approved Zanvastro on 3 September 2026. The medicine, also called zilganersen, treats Alexander disease in children and adults. It is the first treatment approved by that regulator for this rare neurological disorder. The decision concerns the United States and does not create automatic approval in India.
What Alexander disease is
Alexander disease is a progressive disorder of the brain's white matter. White matter carries signals between different parts of the nervous system. The disorder mainly affects astrocytes, which support and protect nerve cells. Damage can later disturb movement, development, swallowing, breathing and other functions.
The usual cause is a harmful variant in the GFAP gene. That gene provides instructions for glial fibrillary acidic protein, or GFAP. Abnormal GFAP accumulates inside astrocytes and disrupts their normal work. The resulting stress can damage surrounding myelin and nervous tissue.
The condition follows an autosomal dominant inheritance pattern. One altered gene copy can therefore cause the disease. Most confirmed cases result from a new, or de novo, variant. Familial cases also occur, especially among some people with slower adult disease.
Why symptoms vary
Alexander disease forms a broad clinical spectrum rather than one fixed pattern. Early-onset disease may cause seizures, feeding problems and loss of developmental skills. Older children can develop weakness, speech difficulties or repeated vomiting. Adults may show walking, swallowing, speech, sleep or autonomic problems.
Doctors use symptoms, brain magnetic resonance imaging and molecular genetic testing. Imaging may show characteristic changes in white matter and the brain stem. A harmful GFAP variant helps establish the diagnosis. A genetic variant of uncertain significance cannot establish it alone.
Until this approval, treatment concentrated on supportive care. Patients might need seizure medicines, nutrition support and physical or speech therapy. Respiratory and swallowing problems require close monitoring. Multidisciplinary care remains important even after a targeted medicine becomes available.
How Zanvastro works
Zanvastro is an antisense oligonucleotide medicine. It uses a short synthetic strand that binds selected genetic messenger material. This reduces production of the disease-driving GFAP protein. The medicine is not gene editing and does not remove the underlying gene variant.
A trained professional injects it into the spinal canal every three months. This route is called intrathecal administration. It delivers medicine near the central nervous system but requires a lumbar puncture. Patients therefore need suitable facilities and continuing medical supervision.
Evidence behind the approval
The regulator reviewed a randomised controlled study involving 49 patients aged two years or older. It also considered an open-label substudy of four younger patients. Participants represented both paediatric and adult disease. Rare-disease trials often need age-specific measures because symptoms differ greatly.
Among patients aged five or above with walking difficulty, treated patients had better walking speed at week 61. Children aged two to four received a broader motor-skills assessment. Their treated group improved while the control group declined. These outcomes supported benefit across different disease presentations.
Evidence for children below two years was necessarily limited. The regulator used drug-level modelling alongside safety information from four treated infants. This supported the broader age indication. Continued follow-up remains important because the youngest group was very small.
Safety, access and unanswered questions
Common reported effects include vomiting, back pain, cough and headache. Post-lumbar-puncture syndrome can also occur. The prescribing information warns about aseptic meningitis. Families and clinicians must weigh these risks against each patient's disease course.
The approval does not mean the disease has been cured. Reducing GFAP may slow or improve some functions without reversing established injury. Long-term durability also needs observation after wider use. Registries can help identify uncommon effects that trials were too small to detect.
Access will depend upon regulatory decisions, specialist centres and affordability. Indian patients cannot assume availability from a United States approval. Any Indian use requires applicable review and lawful supply arrangements. Health systems must also preserve rehabilitation and supportive services.
Conclusion
Zanvastro changes the treatment landscape for Alexander disease in the United States. It directly reduces production of the protein linked with disease injury. Trial results show meaningful benefit, but the evidence base remains small. Safety monitoring and long-term follow-up are therefore vital. Other regulators must independently decide whether local access is justified.